Jnj sirna combo data had no patients achieve primary outcome.
Gsk antisense just under 10 percent got to SVR 24 (functional cure?). Down from 28-29 percent at easl. I would imagine they scrap monotherapy plans for phase 3 (there was a subset with 16 percent SVR). Sequential treatment with interferon data due early next year
Market Data 
Markets 
AI
